Soriatane
Intended to relieve hyperkeratotic plaque lesions to support skin structure normalisation and target cell proliferation.
Soriatane details
- Condition
- Severe Plaque Psoriasis
- Alternative names
- acitretin
- Therapeutic class
- Systemic Retinoid
- Pharmacological class
- Retinoid
- Known off-label uses
- other severe keratinisation disorders
- Contraindications
- pregnancy; severe hepatic or renal impairment; uncontrolled hyperlipidaemia
- Minor side effects
- chapped lips; dry skin; peeling skin
- Moderate side effects
- hair thinning; nail fragility; hypertrichosis
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Originator
- Stiefel Laboratories
- Onset Time
- 2–4 weeks
- Duration
- 1–3 months
- Storage instructions
- Store below 25°C. Keep dry.
- Drug interactions
- Tetracyclines; Methotrexate; Alcohol
- Age restrictions
- Approved for adults.
Serious side effects
severe hepatotoxicity, requires immediate medical attention; pseudotumour cerebri, requires immediate medical attention
Patient summary
intended to relieve hyperkeratotic plaque lesions to support skin structure normalisation and target cell proliferation.
Mechanism of action
Retards epidermal cellular division and normalises keratinocyte cell maturation by binding to nuclear retinoic acid receptors.
Pregnancy and breastfeeding
TGA Category X: Highly teratogenic. Strictly avoid pregnancy during use and for three years after stopping. Breastfeeding: Contraindicated.
What you will receive
Soriatane is the originator brand name, made by Stiefel Laboratories. We use it to identify the medicine and are not affiliated with Stiefel Laboratories.
- The fulfilment partner confirms whether the exact brand or an equivalent containing Acitretin is offered.
- The offered brand, manufacturer and dispatch location depend on the product, destination and partner warehouse.
- Check the final product details at checkout before confirming an order.